A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
The primary objectives of this study are: (safety run-in cohort) to evaluate safety and
tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the
efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and
leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic
colorectal cancer (mCRC).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.